Key result
Bevacizumab combined with chemotherapy linked to fatal concurrent cerebral infarction and pulmonary embolism.
Why the study?
Fatal concurrent arteriovenous thromboembolism following bevacizumab combined with chemotherapy had not been previously reported.
Population
One 55-year-old man with metastatic lung cancer after radical resection
Design
Case report
Follow-up
1 mo
Authors
Loading...
Fatal thromboembolism on bevacizumab in advanced NSCLC warrants vigilance; hypothesis-generating and should not change practice without controlled data.
Case Report (n=1)
Bevacizumab combined with chemotherapy may increase the risk of fatal arteriovenous thromboembolism in patients with advanced lung cancer.
Kong et al. (2022) conducted a case report in Advanced non-small cell lung cancer (n=1). Bevacizumab plus chemotherapy was evaluated on Arteriovenous thrombotic events (cerebral infarction and pulmonary embolism). A 55-year-old man with advanced non-small cell lung cancer developed fatal concurrent cerebral infarction and pulmonary embolism six months after initiating treatment with bevacizumab combined with chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: